RTI Surgical (RTIX) 10-Q 4 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 27, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	RTIX
Entity Registrant Name	RTI SURGICAL, INC.
Entity Central Index Key	1100441
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		57,360,092

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$11,904	$15,703
Accounts receivable - less allowances of $961 at March 31, 2015 and $818 at December 31, 2014	39,666	38,833
Inventories - net	114,908	113,464
Prepaid and other current assets	6,343	6,668
Deferred tax assets - net	22,563	22,828
Total current assets	195,384	197,496
Property, plant and equipment - net	77,290	77,028
Deferred tax assets - net	5,540	6,193
Goodwill	54,887	54,887
Other intangible assets - net	29,129	30,261
Other assets - net	11,975	12,270
Total assets	374,205	378,135
Current Liabilities:
Accounts payable	27,016	26,834
Accrued expenses	20,928	24,689
Current portion of deferred revenue	4,695	5,984
Current portion of short and long-term obligations	6,467	6,479
Total current liabilities	59,106	63,986
Long-term obligations - less current portion	68,275	69,413
Other long-term liabilities	11,538	11,607
Deferred revenue	13,003	12,460
Total liabilities	151,922	157,466
Preferred stock Series A, $.001 par value: 5,000,000 shares authorized; 50,000 shares issued and outstanding	53,688	52,834
Stockholders' equity:
Common stock, $.001 par value: 150,000,000 shares authorized; 57,271,449 and 56,917,414 shares issued and outstanding, respectively	57	57
Additional paid-in capital	416,438	415,702
Accumulated other comprehensive loss	-7,356	-3,881
Accumulated deficit	-240,112	-243,854
Less treasury stock, 228,253 and 180,898 shares, respectively, at cost	-432	-189
Total stockholders' equity	168,595	167,835
Total liabilities and stockholders' equity	$374,205	$378,135

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$961	$818
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	50,000	50,000
Preferred stock, shares outstanding	50,000	50,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	57,271,449	57,271,449
Common stock, shares outstanding	56,917,414	56,917,414
Treasury stock, shares	228,253	180,898

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenues	$68,034	$60,745
Costs of processing and distribution	31,035	34,547
Gross profit	36,999	26,198
Expenses:
Marketing, general and administrative	27,255	25,854
Research and development	3,580	3,832
Total operating expenses	30,835	29,686
Operating income (loss)	6,164	-3,488
Other (expense) income:
Interest expense	-318	-336
Interest income	2	3
Foreign exchange gain (loss)	22	-22
Total other expense - net	-294	-355
Income (loss) before income tax (provision) benefit	5,870	-3,843
Income tax (provision) benefit	-2,128	1,533
Net income (loss)	3,742	-2,310
Convertible preferred dividend	-808	-750
Net income (loss) applicable to common shares	2,934	-3,060
Other comprehensive (loss) gain:
Unrealized foreign currency translation (loss) gain	-3,475	49
Comprehensive loss	($541)	($3,011)
Net income (loss) per common share - basic	$0.05	($0.05)
Net income (loss) per common share - diluted	$0.05	($0.05)
Weighted average shares outstanding - basic	57,087,497	56,451,646
Weighted average shares outstanding - diluted	57,949,224	56,451,646

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
In Thousands					Series A Preferred Stock [Member]
Beginning Balance at Dec. 31, 2014	$167,835		$57	$415,702		($3,881)	($243,854)	($189)
Net income	3,742						3,742
Foreign currency translation adjustment	-3,475					-3,475
Exercise of common stock options	714			714
Stock-based compensation	883			883
Purchase of treasury stock	-243							-243
Amortization of preferred stock Series A issuance costs	-307	-46			-46
Preferred stock Series A dividend		-808			-808
Change in tax benefit from stock- based compensation	-7			-7
Ending Balance at Mar. 31, 2015	$168,595		$57	$416,438		($7,356)	($240,112)	($432)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	$3,742	($2,310)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization expense	3,966	3,664
Provision for bad debts and product returns	615	53
Provision for inventory write-downs	1,196	1,314
Amortization of deferred revenue	-2,746	-1,799
Deferred income tax provision (benefit)	258	-1,039
Stock-based compensation	573	490
Other	525	15
Change in assets and liabilities:
Accounts receivable	-1,924	-299
Inventories	-4,283	1,081
Accounts payable	171	-650
Accrued expenses	-3,864	-2,970
Deferred revenue	2,000
Other operating assets and liabilities	777	-857
Net cash provided by (used in) operating activities	1,006	-3,307
Cash flows from investing activities:
Purchases of property, plant and equipment	-4,265	-4,936
Patent and acquired intangible asset costs	-22	-217
Net cash used in investing activities	-4,287	-5,153
Cash flows from financing activities:
Proceeds from exercise of common stock options	714	292
Proceeds from long-term obligations		4,000
Net proceeds from short-term obligations	510	1,233
Payments on long-term obligations	-1,513	-20
Other financing activities	-160	-122
Net cash (used in) provided by financing activities	-449	5,383
Effect of exchange rate changes on cash and cash equivalents	-69	-179
Net decrease in cash and cash equivalents	-3,799	-3,256
Cash and cash equivalents, beginning of period	15,703	18,721
Cash and cash equivalents, end of period	11,904	15,465
Supplemental cash flow disclosure:
Cash paid for interest	389	351
Cash paid (refunds) for income taxes, net	754	-79
Change in accrual for purchases of property, plant and equipment	30	1,059
Stock-based compensation related to severance	310
Change in accrued dividend payable	$808	$750

Operations_and_Organization

Operations and Organization	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Operations and Organization	1	Operations and Organization
	The Company is a leader in the use of natural tissues, metals and synthetics to produce orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes. The Company processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing proprietary BIOCLEANSE®, TUTOPLAST® and CANCELLE® SP sterilization processes, and manufactures metal and synthetic implants, for distribution to hospitals and surgeons. The Company processes tissue at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany, and manufactures metal and synthetic implants in Marquette, Michigan and Greenville, North Carolina. The Company distributes its implants and services in all 50 states and in over 45 countries worldwide.

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	2	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, which the Company considers necessary for a fair presentation of the results of operations for the periods shown. The condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, and, therefore, do not include all information and footnotes necessary for a fair presentation of consolidated financial position, results of operations, comprehensive income (loss) and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The results of operations for any interim period are not necessarily indicative of the results to be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.
	The condensed consolidated financial statements include the accounts of RTI Surgical, Inc. and its wholly owned subsidiaries, Pioneer Surgical Technology, Inc. (“Pioneer”), Tutogen Medical, Inc. (“TMI”), RTI Surgical, Inc. – Cardiovascular (inactive), Biological Recovery Group, Inc. (inactive) and RTI Services, Inc. (inactive). The condensed consolidated financial statements also include the accounts of RTI Donor Services, Inc. (“RTIDS”), which is a controlled entity.

Recently_Issued_Accounting_Sta

Recently Issued Accounting Standards	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Recently Issued Accounting Standards	3	Recently Issued Accounting Standards
	Simplifying the Presentation of Debt Issuance Costs — In April 2015, the FASB issued Accounting Standard Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs. This ASU simplifies the accounting for debt issuance costs by requiring such costs to be presented as a direct deduction from the related debt liability rather than as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The ASU requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The ASU will impact the Company’s classification of deferred financing costs as the Company currently records these costs in other assets, see Note 9. The Company is evaluating the impact of this ASU on its unaudited condensed consolidated financial statements and has not yet determined if it will early adopt the ASU.
	Presentation of Financial Statements-Going Concern — In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40).” The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect to early adopt this guidance and does not believe that the adoption of this guidance will have a material impact on its unaudited condensed consolidated financial statements.
	Revenue from Contracts with Customers — In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be annual reporting periods beginning after December 15, 2016, using one of two retrospective application methods. The Company has not yet determined the potential effects, if any, on its unaudited condensed consolidated financial statements.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	4	Stock-Based Compensation
	The Company has six stock-based compensation plans under which employees, consultants and outside directors have received stock options and restricted stock awards. The Company’s policy is to grant stock options at an exercise price equal to 100% of the market value of a share of common stock at closing on the date of the grant. The Company’s stock options generally have ten-year contractual terms and vest over a one to five year period from the date of grant. The Company’s policy is to grant restricted stock awards at a fair value equal to 100% of the market value of a share of common stock at closing on the date of the grant. The Company’s restricted stock awards generally vest over one to three year periods.
	2015 Incentive Compensation Plan – On April 14, 2015, the Company’s stockholders approved and adopted the 2015 Incentive Compensation Plan, (the “2015 Plan”). The 2015 Plan provides for the grant of incentive and nonqualified stock options and restricted stock to key employees, including officers and directors of the Company and consultants and advisors. The 2015 Plan allows for up to 4,656,587 shares of common stock to be issued with respect to awards granted.
	1998 Stock Option Plan, 2004 Equity Incentive Plan, 2010 Equity Incentive Plan, TMI 1996 Stock Option Plan and TMI 2006 Incentive and Non-Statutory Stock Option Plan – The Company adopted equity incentive plans in 1998 (the “1998 Plan”), 2004 (the “2004 Plan”) and 2010 (the “2010 Plan”) and in connection with the merger with TMI in 2008, the Company assumed the TMI 1996 Stock Option Plan (the “1996 Plan”) and the TMI 2006 Incentive and Non-Statutory Stock Option Plan (the “2006 Plan”), which provided for the grant of incentive and nonqualified stock options and restricted stock to key employees, including officers and directors of the Company and consultants and advisors. With the adoption of the 2015 Plan, new stock options and restricted stock may no longer be awarded under the 1998 Plan, 2004 Plan, 2010 Plan, 1996 Plan or the 2006 Plan.
	Stock Options
	As of March 31, 2015, there was $4,079 of total unrecognized stock-based compensation related to nonvested stock options. That expense is expected to be recognized over a weighted-average period of 3.64 years.
	Stock options outstanding, exercisable and available for grant at March 31, 2015 are summarized as follows:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life (Years)
	Outstanding at January 1, 2015		5,735,784		$	4.34
	Granted		915,000			5.23
	Exercised		(235,500	)		3.03
	Forfeited or expired		(24,500	)		3.96
	Outstanding at March 31, 2015		6,390,784		$	4.52		6.12	$	5,569
	Vested or expected to vest at March 31, 2015		6,062,442		$	4.51		5.94	$	5,408
	Exercisable at March 31, 2015		3,720,984		$	4.7		4.36	$	3,477
	Available for grant at March 31, 2015		686,587
	The aggregate intrinsic value in the tables above represents the total pre-tax intrinsic value of stock options for which the fair market value of the underlying common stock exceeded the respective stock option exercise price.
	Other information concerning stock options are as follows:
		For the Three Months Ended
		March 31,
		2015			2014
	Weighted average fair value of stock options granted	$	2.48		$	1.84
	Aggregate intrinsic value of stock options exercised		510			51
	The aggregate intrinsic value of stock options exercised in a period represents the pre-tax cumulative difference between the fair market value of the underlying common stock and the stock option exercise prices, of the stock options exercised during the period.
	Restricted Stock Awards
	During the first quarter of 2015, the Company granted 110,000 shares of restricted stock with a weighted-average grant date fair value of $5.23 per share which vest over a three year period. As of March 31, 2015, there was $881 of total unrecognized stock-based compensation related to time-based, nonvested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 1.43 years.
	For the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation as follows:
		For the Three Months Ended
		March 31,
		2015			2014
	Stock-based compensation:
	Costs of processing and distribution	$	33		$	33
	Marketing, general and administrative		525			442
	Research and development		15			15
	Total	$	573		$	490

Net_Income_Loss_Per_Common_Sha

Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	5	Net Income (Loss) Per Common Share
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net income (loss) per common share is presented below:
		For the Three Months Ended
		March 31,
		2015		2014
	Basic shares		57,087,497		56,451,646
	Effect of dilutive securities:
	Stock options		861,727		—
	Diluted shares		57,949,224		56,451,646
	For the three months ended March 31, 2015 and 2014, approximately 1,695,436 and 4,214,548, respectively, of issued stock options were not included in the computation of diluted net income or loss per common share because they were anti-dilutive since their exercise price exceeded the market price. For the three months ended March 31, 2014, options to purchase 282,606 of common stock were not included in the computation of diluted loss per share because dilutive shares are not factored into this calculation when a net loss is reported.
	For the three months ended March 31, 2015 and 2014, 50,000 shares of convertible preferred stock and accrued but unpaid dividends were anti-dilutive on an as if-converted basis and were not included in the computation of diluted net income (loss) per common share.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	6	Inventories
	Inventories by stage of completion are as follows:
		March 31,		December 31,
		2015		2014
	Unprocessed tissue and raw materials	$	29,285	$	29,429
	Tissue and work in process		43,042		44,688
	Implantable tissue and finished goods		40,380		37,150
	Supplies		2,201		2,197
		$	114,908	$	113,464
	For the three months ended March 31, 2015 and 2014, the Company had inventory write-downs of $1,196 and $1,314, respectively, relating primarily to product obsolescence.

Property_Plant_and_Equipment

Property, Plant and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	7	Property, Plant and Equipment
	Property, plant and equipment are as follows:
		March 31,			December 31,
		2015			2014
	Land	$	2,305		$	2,474
	Buildings and improvements		62,808			49,483
	Processing equipment		46,288			45,878
	Surgical instruments		10,492			9,428
	Office equipment, furniture and fixtures		4,137			3,863
	Computer equipment and software		7,428			7,674
	Construction in process		8,559			20,957
	Office equipment under capital leases		151			152
			142,168			139,909
	Less accumulated depreciation		(64,878	)		(62,881	)
		$	77,290		$	77,028
	Depreciation expense of property, plant and equipment was $2,944 and $2,536 for the three months ended March 31, 2015 and 2014, respectively.

Other_Intangible_Assets

Other Intangible Assets	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Other Intangible Assets	8	Other Intangible Assets
	Other intangible assets are as follows:
		March 31, 2015				December 31, 2014
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Patents	$	11,328	$	2,875	$	11,420	$	2,727
	Acquired licensing rights		10,850		6,841		10,850		6,538
	Marketing and procurement intangible assets		22,143		5,476		22,342		5,086
	Total	$	44,321	$	15,192	$	44,612	$	14,351
	Marketing and procurement intangible assets include the following: procurement contracts, trademarks, selling and marketing relationships, customer lists and non-compete agreements.
	Amortization expense of other intangible assets for the three months ended March 31, 2015 and 2014 was $1,022 and $1,128, respectively. At March 31, 2015, management’s estimates of future amortization expense for the next five years are as follows:
		Amortization
		Expense
	2015	$	3,000
	2016		3,400
	2017		3,300
	2018		3,300
	2019		3,300
		$	16,300

Other_Assets

Other Assets	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	9	Other Assets
	Other assets are as follows:
		March 31,		December 31,
		2015		2014
	Indemnification asset	$	11,342	$	11,394
	Other		633		876
		$	11,975	$	12,270
	On July 16, 2013, the Company completed its acquisition of Pioneer. Under the terms of the merger agreement dated June 12, 2013, the Company acquired Pioneer for $126,307 in cash. The transaction was funded through a combination of cash on hand, a new credit facility and a concurrent private placement of convertible preferred equity with Water Street Healthcare Partners (“Water Street”). Under the acquisition agreement, Pioneer deposited $13,000 in an escrow account and indemnified the Company for up to $13,000 for various outstanding legal issues. At acquisition, the Company recorded a $13,000 indemnification asset and a corresponding $13,000 indemnification liability. At March 31, 2015, other assets include $11,342 of remaining long-term indemnification assets. Under the acquisition agreement, the Company has submitted claims against the escrow account during the initial escrow period which ended on October 16, 2014. Under certain provisions of the agreement, the claims period for certain claims may be extended to 30 months after the closing date. The resolution of submitted claims will occur after the claims period ends.
	Interest expense associated with the amortization of debt issuance costs for both the three months ended March 31, 2015 and 2014 was $35. The remaining unamortized debt issuance costs are included in Other in the table above.

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Other Liabilities Disclosure [Abstract]
Accrued Expenses	10	Accrued Expenses
	Accrued expenses are as follows:
		March 31,		December 31,
		2015		2014
	Accrued compensation	$	5,787	$	6,220
	Accrued severance charges		1,413		2,771
	Accrued distributor commissions		2,256		3,159
	Accrued donor recovery fees		2,860		3,249
	Accrued taxes		1,737		1,249
	Accrued restructuring charges		—		13
	Other		6,875		8,028
		$	20,928	$	24,689
	The Company accrues for the estimated donor recovery fees due to third party recovery agencies as tissue is received.

Short_and_LongTerm_Obligations

Short and Long-Term Obligations	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Short and Long-Term Obligations	11	Short and Long-Term Obligations
	Short and long-term obligations are as follows:
		March 31,			December 31,
		2015			2014
	Term loan	$	57,875		$	59,375
	Credit facilities		16,798			16,435
	Capital leases		69			82
	Total		74,742			75,892
	Less current portion		(6,467	)		(6,479	)
	Long-term portion	$	68,275		$	69,413
	The Company obtained from TD Bank and Regions Bank, a 5-year, $80,000 senior secured facility, which includes a $60,000 term loan and a $20,000 revolving credit facility, that matures on July 16, 2018, with a variable interest rate between 100 and 175 basis points in excess of the one month LIBOR rate. At March 31, 2015, the interest rate for the term loan and revolving credit facility is 1.68%. The facility is secured by substantially all the assets of the Company and its subsidiaries and guaranteed by the Company’s domestic subsidiaries, other than RTIDS. As of March 31, 2015, there was $15,250 outstanding on the revolving credit facility. The term loan facility requires aggregate principal payments of $18,000 from January 1, 2015 through June 30, 2018, with a final balloon principal payment at the end of the loan agreement. The credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, as well as payment of dividends, while requiring a minimum cash balance on hand of $10,000 and certain financial covenant ratios. On October 15, 2014, the Company entered into a second amendment to the second amended and restated loan agreement with TD Bank, N.A. and Regions Bank, which amended the loan agreement to remove certain financial covenants. The Company was in compliance with all financial covenants related to its term loan as of March 31, 2015.
	In addition to the credit facility with TD Bank and Regions Bank, the Company has through its German subsidiary, three credit facilities with three German banks as of March 31, 2015. Under the terms of the revolving credit facilities, the Company may borrow up to 1,700 Euro, or approximately $1,845, for working capital needs. The 1,000 Euro revolving credit facility is secured by a mortgage on the Company’s German facility. The 500 Euro revolving credit facility is secured by accounts receivable of the Company’s German subsidiary. The 200 Euro revolving credit facility is unsecured. The current interest rates for these lines of credit vary from 2.55% to 8.50%. As of March 31, 2015, there was $1,548 outstanding on revolving credit facilities with German banks.
	The total available credit on the Company’s four revolving credit facilities at March 31, 2015 was $5,047. The Company was in compliance with all financial covenants related to its revolving credit facilities as of March 31, 2015.
	The Company has capital leases with interest rates ranging from 1.49% to 2.85% and maturity dates through 2017. The $69 representing future maturities of capital leases includes interest in the amount of $1 at March 31, 2015. The present value of minimum lease payments as of March 31, 2015 was $68.
	As of March 31, 2015, contractual maturities of long-term obligations are as follows:
		Term Loan			Credit			Capital		Total
					Facilities			Leases
	2015	$	3,750		$	1,548		$	32	$	5,330
	2016		4,500			—			33		4,533
	2017		5,250			—			4		5,254
	2018		44,375			15,250			—		59,625
		$	57,875		$	16,798		$	69	$	74,742

Other_LongTerm_Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Other Long-Term Liabilities	12	Other Long-Term Liabilities
	Other long-term liabilities are as follows:
		March 31,		December 31,
		2015		2014
	Indemnification liability	$	11,342	$	11,394
	Other		196		213
		$	11,538	$	11,607
	As described in Note 9, the Company recorded a $13,000 indemnification liability on the date of the acquisition of Pioneer.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	13	Income Taxes
	The Company expects its deferred tax assets of $28,103, net of the valuation allowance at March 31, 2015, of $906, to be realized through the generation of future taxable income and the reversal of existing taxable temporary differences.
	Valuation allowances are established when necessary to reduce deferred tax assets to amounts which are more likely than not to be realized. As such, valuation allowances of $906 and $959 have been established at March 31, 2015 and December 31, 2014, respectively, against a portion of the deferred tax assets relating to certain net operating loss carryforwards.
	U.S. income taxes have not been provided for on the undistributed earnings of the Company’s foreign subsidiaries. It is not practicable to estimate the amount of tax that might be payable. The Company’s intention is to indefinitely reinvest earnings of its foreign subsidiaries.
	The Company evaluates the need for deferred tax asset valuation allowances based on a more likely than not standard. The ability to realize deferred tax assets depends on the ability to generate sufficient taxable income within the carryback or carryforward periods provided for in the tax law for each applicable tax jurisdiction.
	The assessment regarding whether a valuation allowance is required or should be adjusted also considers all available positive and negative evidence. It is difficult to conclude a valuation allowance is not required when there is significant objective and verifiable negative evidence, such as cumulative losses in recent years. The Company utilizes a rolling three years of actual results as the primary measure of cumulative losses in recent years.
	When evaluating whether the Company has overcome the significant negative evidence that resulted from cumulative losses in recent years, the Company adjusted its historical loss for items that the Company determined were not indicative of its ability to generate taxable income in future years. The Company’s U.S. operations are in a cumulative income position after adjusting for the items that were not indicative of its ability to generate taxable income in future years. The Company considers this objectively verifiable evidence that its current U.S. operations existing on March 31, 2015, have consistently demonstrated the ability to operate at a profit. The Company believes that this evidence is sufficient to overcome the unadjusted cumulative U.S. losses in recent years. The Company has a history of utilizing 100 percent of its U.S. deferred taxes assets before they expire and the forecasts of taxable earnings project a complete realization of all U.S. deferred tax assets before they expire, including under stressed scenarios.
	The Company’s foreign operations are in a cumulative loss position after adjusting for items not indicative of its ability to generate taxable income in future years. As of March 31, 2015, the Company’s foreign deferred tax assets primarily relate to net operating loss carryforwards. In general, the Company’s foreign net operating loss carryforwards can be carried forward indefinitely. Future taxable income exclusive of reversing temporary differences and carryfowards is one source of taxable income available that can be used to realize tax benefits. It is the Company’s intent, if foreign operations do not generate cumulative income in the near future, to employ a tax planning action that will allow the Company to generate foreign taxable earnings and utilize certain foreign net operating losses. As a result, the Company has not recorded an additional valuation allowance charge.
	Upon considering all of the available positive and negative evidence, and the extent to which that evidence was objectively verifiable, the Company determined that the positive evidence outweighed the negative evidence and the deferred tax assets are more-likely-than-not realizable, as of March 31, 2015.
	The Company will continue to regularly assess the realizability of our deferred tax assets. Changes in historical earnings performance and future earnings projections, among other factors, may cause the Company to adjust its valuation allowance, which would impact the Company’s income tax expense in the period the Company determines that these factors have changed.
	One of the Company’s foreign subsidiaries is undergoing an examination by the German tax authorities. The foreign examination covers the foreign subsidiary’s 2010 through 2012 tax years.

Preferred_Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Preferred Stock	14	Preferred Stock
	On June 12, 2013, the Company and Water Street entered into an investment agreement. Pursuant to the terms of the investment agreement, the Company issued $50,000 of convertible preferred equity to Water Street in a private placement which closed on July 16, 2013. The Preferred Stock accrues dividends at a rate of 6% per annum. To the extent dividends are not paid in cash in any quarter, the dividends which have accrued on each outstanding share of Preferred Stock during such three-month period will accumulate until paid in cash or converted to common stock.
	Preferred stock is as follows:
		March 31,			December 31,
		2015			2014
	Preferred shares issuance	$	50,000		$	50,000
	Preferred shares issuance costs		(1,290	)		(1,290	)
	Net proceeds		48,710			48,710
	Amortization of preferred shares issuance costs		307			261
	Accrued dividend payable		4,671			3,863
		$	53,688		$	52,834

Restructuring_Charges

Restructuring Charges	3 Months Ended
	Mar. 31, 2015
Restructuring Charges	15	Restructuring Charges
	The Company instituted a restructuring plan primarily related to termination of employees and a location closure as a result of the integration activities following the acquisition of Pioneer, which resulted in $2,881 of expenses for the year ended December 31, 2013. The total restructuring charges were paid in full as of February 28, 2015. The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 10.
	Accrued restructuring charges at January 1, 2015	$	13
	Cash payments		(13	)
	Accrued restructuring charges at March 31, 2015	$	—
Employee Severance [Member]
Restructuring Charges	16	Severance Charges
	The Company recorded severance charges related to the termination of former employees as a result of the Company flattening its organizational structure, which resulted in $4,798 of expenses for the year ended December 31, 2014. The total severance charges are expected to be paid in full prior to December 31, 2015. Severance payments are made to terminated employees over periods ranging from one month to twelve months and will not have a material impact on cash flows of the Company in any quarterly period. The following table includes a rollforward of severance charges included in accrued expenses, see Note 10.
	Accrued severance charges at January 1, 2015	$	2,771
	Severance cash payments		(1,048	)
	Stock based compensation		(310	)
	Accrued severance charges at March 31, 2015	$	1,413

Legal_Actions

Legal Actions	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Actions	17	Legal Actions
	The Company is, from time to time, involved in litigation relating to claims arising out of its operations in the ordinary course of business. The Company believes that none of these claims that were outstanding as of March 31, 2015 will have a material adverse impact on its financial position or results of operations.
	Coloplast—The Company is presently named as co-defendant along with other companies in a small percentage of the transvaginal surgical mesh (“TSM”) mass tort claims being brought in various state and federal courts. The TSM litigation has as its catalyst various Public Health Notifications issued by the U.S. Food and Drug Administration (“FDA”) with respect to the placement of certain TSM implants that were the subject of 510k regulatory clearance prior to their distribution. The Company does not process or otherwise manufacture for distribution in the U.S. any implants that were the subject of these FDA Public Health Notifications. The Company denies any allegations against it and intends to vigorously defend itself.
	In addition to claims made directly against the Company, Coloplast, a distributor of TSM’s and certain allografts processed and private labeled for them under a contract with the Company, has also been named as a defendant in individual TSM cases in various federal and state courts. Coloplast requested that the Company indemnify or defend Coloplast in those claims which allege injuries caused by the Company’s allograft implants, and on April 24, 2014, Coloplast sued RTI Surgical, Inc. in the Fourth Judicial District of Minnesota for declaratory relief and breach of contract. On December 11, 2014, Coloplast entered into a settlement agreement with RTI Surgical, Inc. and Tutogen Medical, Inc. (the “Company Parties”) resulting in dismissal of the case. Under the terms of the settlement agreement, the Company Parties are responsible for the defense and indemnification of two categories of present and future claims: (1) tissue only (where Coloplast is solely the distributor of Company processed allograft tissue and no Coloplast-manufactured or distributed synthetic mesh is identified) (“Tissue Only Claims”), and (2) tissue plus non-Coloplast synthetic mesh (“Tissue-Non-Coloplast Claims”). There are presently 333 Tissue Only Claims and 354 Tissue-Non-Coloplast Claims for which the Company Parties are providing defense and indemnification. The defense and indemnification of these cases are covered under the Company’s insurance policy subject to a reservation of rights by the insurer.
	Based on the current information available to the Company, it is not possible to evaluate and estimate with reasonable certainty the impact that current or any future TSM litigation may have on the Company.
	The Company’s accounting policy is to accrue for legal costs as they are incurred.

Regulatory_Actions

Regulatory Actions	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Regulatory Actions	18	Regulatory Actions
	In the quarter ended September 30, 2014, the Company received a letter from the FDA regarding the Company’s map3® cellular allogeneic bone graft. The letter addresses some technical aspects of the processing of the map3® allograft, as well as language included on the Company’s website. The Company has submitted information and remains in discussion with the FDA. The Company believes that in both developing and processing of map3®, the Company has properly considered the relevant regulatory requirements. Additionally, the Company has removed the relevant information from the website pending thorough review and revisions as needed. The Company is committed to resolving the concerns raised by the FDA. However, it is not possible to predict the specific outcome or timing of a resolution at this time.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	19	Commitments and Contingencies
	Distribution Agreement with Davol - On July 13, 2009, the Company and Davol amended their previous distribution agreement with TMI for human dermis implants. Under the amended agreement; 1) Davol paid the Company $8,000 in non-refundable fees for exclusive distribution rights for the distribution to the breast reconstruction market until July 13, 2019; 2) the exclusive worldwide distribution agreement related to the hernia market was extended to July 13, 2019; and 3) Davol agreed to pay the Company certain additional exclusive distribution rights fees contingent upon the achievement of certain revenue milestones by Davol during the duration of the contract. In the fourth quarter of 2010, Davol paid the first revenue milestone payment of $3,500. The non-refundable fees and the fees associated with distributions of processed tissue are considered to be a single unit of accounting. Accordingly, the $8,000 and $3,500 exclusivity payments have been deferred and are being recognized as other revenues on a straight-line basis over the initial term of the amended contract of ten years, and the remaining term of the amended contract, respectively. The straight-line method approximated the pattern of implant distribution based on this distribution agreement’s contractual annual minimum purchase requirements. Davol did not achieve certain revenue growth milestones which resulted in Davol relinquishing its exclusive distribution rights in the hernia market effective January 1, 2013 and the breast reconstruction market effective January 1, 2015. As a result, the Company recognized additional deferred revenue as other revenues during the three months ended March 31, 2013 and 2015, of $1,715 and $1,500, respectively, due to the acceleration of deferred revenue recognition relating to Davol relinquishing its exclusive distribution rights in the hernia and the breast reconstruction markets.

Segment_Data

Segment Data	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Data	20	Segment Data
	The Company distributes human tissue, bovine and porcine animal tissue, metal and synthetic implants through various distribution channels. The Company operates in one reportable segment comprised of six lines of business. The Company’s lines of business are comprised primarily of six categories: spine; sports medicine; bone graft substitutes (“BGS”) and general orthopedic; ortho fixation; surgical specialties and dental. Discrete financial information is not available for these six lines of business. The following table presents revenues from these six categories and other revenues for the three months ended March 31, 2015 and 2014, respectively:
		For the Three Months Ended
		March 31,
		2015			2014
		(In Thousands)
	Revenues:
	Spine	$	19,379		$	19,063
	Sports medicine		12,107			11,360
	BGS and general orthopedic		10,929			8,147
	Ortho fixation		10,637			7,495
	Surgical specialties		6,010			7,278
	Dental		4,755			4,646
	Other revenues		4,217			2,756
	Total revenues	$	68,034		$	60,745
	Domestic revenues		62,688			54,815
	International revenues		5,346			5,930
	Total revenues	$	68,034		$	60,745
	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
		For the Three Months Ended
		March 31,
		2015			2014
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		20	%		17	%
	Medtronic, Inc.		9	%		14	%
	Davol, Inc.		4	%		7	%
	International		8	%		10	%
	The following table presents property, plant and equipment - net by significant geographic location:
		March 31,			December 31,
		2015			2014
	Property, plant and equipment - net:
	Domestic	$	64,590		$	63,009
	International		12,700			14,019
	Total	$	77,290		$	77,028

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	21	Subsequent Events
	The Company evaluated subsequent events as of the issuance date of the condensed consolidated financial statements as defined by FASB ASC 855 Subsequent Events, and identified no subsequent events that require adjustment to, or disclosure of, in these condensed consolidated financial statements.

Recently_Issued_Accounting_Sta1

Recently Issued Accounting Standards (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Changes and Error Corrections [Abstract]
Simplifying the Presentation of Debt Issuance Costs	Simplifying the Presentation of Debt Issuance Costs — In April 2015, the FASB issued Accounting Standard Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Topic 835): Simplifying the Presentation of Debt Issuance Costs. This ASU simplifies the accounting for debt issuance costs by requiring such costs to be presented as a direct deduction from the related debt liability rather than as an asset. Debt disclosures will include the face amount of the debt liability and the effective interest rate. The ASU requires retrospective application and represents a change in accounting principle. The update is effective for fiscal years beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The ASU will impact the Company’s classification of deferred financing costs as the Company currently records these costs in other assets, see Note 9. The Company is evaluating the impact of this ASU on its unaudited condensed consolidated financial statements and has not yet determined if it will early adopt the ASU.
Presentation of Financial Statements - Going Concern	Presentation of Financial Statements-Going Concern — In August 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40).” The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect to early adopt this guidance and does not believe that the adoption of this guidance will have a material impact on its unaudited condensed consolidated financial statements.
Revenue from Contracts with Customers	Revenue from Contracts with Customers — In May 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The effective date will be annual reporting periods beginning after December 15, 2016, using one of two retrospective application methods. The Company has not yet determined the potential effects, if any, on its unaudited condensed consolidated financial statements.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options Outstanding, Exercisable and Available for Grant	Stock options outstanding, exercisable and available for grant at March 31, 2015 are summarized as follows:
		Number of			Weighted		Weighted		Aggregate
		Shares			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Life (Years)
	Outstanding at January 1, 2015		5,735,784		$	4.34
	Granted		915,000			5.23
	Exercised		(235,500	)		3.03
	Forfeited or expired		(24,500	)		3.96
	Outstanding at March 31, 2015		6,390,784		$	4.52		6.12	$	5,569
	Vested or expected to vest at March 31, 2015		6,062,442		$	4.51		5.94	$	5,408
	Exercisable at March 31, 2015		3,720,984		$	4.7		4.36	$	3,477
	Available for grant at March 31, 2015		686,587
Other Information Concerning Stock Options	Other information concerning stock options are as follows:
		For the Three Months Ended
		March 31,
		2015			2014
	Weighted average fair value of stock options granted	$	2.48		$	1.84
	Aggregate intrinsic value of stock options exercised		510			51
Stock-Based Compensation Recognized	For the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation as follows:
		For the Three Months Ended
		March 31,
		2015			2014
	Stock-based compensation:
	Costs of processing and distribution	$	33		$	33
	Marketing, general and administrative		525			442
	Research and development		15			15
	Total	$	573		$	490

Net_Income_Loss_Per_Common_Sha1

Net Income (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted net income (loss) per common share is presented below:
		For the Three Months Ended
		March 31,
		2015		2014
	Basic shares		57,087,497		56,451,646
	Effect of dilutive securities:
	Stock options		861,727		—
	Diluted shares		57,949,224		56,451,646

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Components of Inventories	Inventories by stage of completion are as follows:
		March 31,		December 31,
		2015		2014
	Unprocessed tissue and raw materials	$	29,285	$	29,429
	Tissue and work in process		43,042		44,688
	Implantable tissue and finished goods		40,380		37,150
	Supplies		2,201		2,197
		$	114,908	$	113,464

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	Property, plant and equipment are as follows:
		March 31,			December 31,
		2015			2014
	Land	$	2,305		$	2,474
	Buildings and improvements		62,808			49,483
	Processing equipment		46,288			45,878
	Surgical instruments		10,492			9,428
	Office equipment, furniture and fixtures		4,137			3,863
	Computer equipment and software		7,428			7,674
	Construction in process		8,559			20,957
	Office equipment under capital leases		151			152
			142,168			139,909
	Less accumulated depreciation		(64,878	)		(62,881	)
		$	77,290		$	77,028
	Depreciation expense of property, plant and equipment was $2,944 and $2,536 for the three months ended March 31, 2015 and 2014, respectively.

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Other Intangible Assets	Other intangible assets are as follows:
		March 31, 2015				December 31, 2014
		Gross		Accumulated		Gross		Accumulated
		Carrying		Amortization		Carrying		Amortization
		Amount				Amount
	Patents	$	11,328	$	2,875	$	11,420	$	2,727
	Acquired licensing rights		10,850		6,841		10,850		6,538
	Marketing and procurement intangible assets		22,143		5,476		22,342		5,086
	Total	$	44,321	$	15,192	$	44,612	$	14,351
Estimates of Future Amortization Expense	At March 31, 2015, management’s estimates of future amortization expense for the next five years are as follows:
		Amortization
		Expense
	2015	$	3,000
	2016		3,400
	2017		3,300
	2018		3,300
	2019		3,300
		$	16,300

Other_Assets_Tables

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other Assets	Other assets are as follows:
		March 31,		December 31,
		2015		2014
	Indemnification asset	$	11,342	$	11,394
	Other		633		876
		$	11,975	$	12,270

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Other Liabilities Disclosure [Abstract]
Accrued Expenses	Accrued expenses are as follows:
		March 31,		December 31,
		2015		2014
	Accrued compensation	$	5,787	$	6,220
	Accrued severance charges		1,413		2,771
	Accrued distributor commissions		2,256		3,159
	Accrued donor recovery fees		2,860		3,249
	Accrued taxes		1,737		1,249
	Accrued restructuring charges		—		13
	Other		6,875		8,028
		$	20,928	$	24,689

Short_and_LongTerm_Obligations1

Short and Long-Term Obligations (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Short and Long-Term Obligations	Short and long-term obligations are as follows:
		March 31,			December 31,
		2015			2014
	Term loan	$	57,875		$	59,375
	Credit facilities		16,798			16,435
	Capital leases		69			82
	Total		74,742			75,892
	Less current portion		(6,467	)		(6,479	)
	Long-term portion	$	68,275		$	69,413
Contractual Maturities of Short and Long-Term Obligations	As of March 31, 2015, contractual maturities of long-term obligations are as follows:
		Term Loan			Credit			Capital		Total
					Facilities			Leases
	2015	$	3,750		$	1,548		$	32	$	5,330
	2016		4,500			—			33		4,533
	2017		5,250			—			4		5,254
	2018		44,375			15,250			—		59,625
		$	57,875		$	16,798		$	69	$	74,742

Other_LongTerm_Liabilities_Tab

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Schedule of Other Long-Term Liabilities	Other long-term liabilities are as follows:
		March 31,		December 31,
		2015		2014
	Indemnification liability	$	11,342	$	11,394
	Other		196		213
		$	11,538	$	11,607

Preferred_Stock_Tables

Preferred Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Schedule of Preferred Stock	Preferred stock is as follows:
		March 31,			December 31,
		2015			2014
	Preferred shares issuance	$	50,000		$	50,000
	Preferred shares issuance costs		(1,290	)		(1,290	)
	Net proceeds		48,710			48,710
	Amortization of preferred shares issuance costs		307			261
	Accrued dividend payable		4,671			3,863
		$	53,688		$	52,834

Restructuring_Charges_Tables

Restructuring Charges (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Restructuring Charges	The following table includes a rollforward of restructuring charges included in accrued expenses, see Note 10.
	Accrued restructuring charges at January 1, 2015	$	13
	Cash payments		(13	)
	Accrued restructuring charges at March 31, 2015	$	—
Employee Severance [Member]
Schedule of Restructuring Charges	The following table includes a rollforward of severance charges included in accrued expenses, see Note 10.
	Accrued severance charges at January 1, 2015	$	2,771
	Severance cash payments		(1,048	)
	Stock based compensation		(310	)
	Accrued severance charges at March 31, 2015	$	1,413

Segment_Data_Tables

Segment Data (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Revenues from Tissue Distribution and Other Revenues	The following table presents revenues from these six categories and other revenues for the three months ended March 31, 2015 and 2014, respectively:
		For the Three Months Ended
		March 31,
		2015			2014
		(In Thousands)
	Revenues:
	Spine	$	19,379		$	19,063
	Sports medicine		12,107			11,360
	BGS and general orthopedic		10,929			8,147
	Ortho fixation		10,637			7,495
	Surgical specialties		6,010			7,278
	Dental		4,755			4,646
	Other revenues		4,217			2,756
	Total revenues	$	68,034		$	60,745
	Domestic revenues		62,688			54,815
	International revenues		5,346			5,930
	Total revenues	$	68,034		$	60,745
Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution	The following table presents percentage of total revenues derived from the Company’s largest distributors and international distribution:
		For the Three Months Ended
		March 31,
		2015			2014
	Percent of revenues derived from:
	Distributor
	Zimmer, Inc.		20	%		17	%
	Medtronic, Inc.		9	%		14	%
	Davol, Inc.		4	%		7	%
	International		8	%		10	%
Schedule of Property, Plant and Equipment - Net by Significant Geographic Location	The following table presents property, plant and equipment - net by significant geographic location:
		March 31,			December 31,
		2015			2014
	Property, plant and equipment - net:
	Domestic	$	64,590		$	63,009
	International		12,700			14,019
	Total	$	77,290		$	77,028

Operations_and_Organization_Ad

Operations and Organization - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	State
	Country
Operations And Organization [Line Items]
Number of states that receive distribution	50
Number of countries that receive distribution	45
Alachua, Florida [Member]
Operations And Organization [Line Items]
Number of operating facilities	2
Neunkirchen, Germany [Member]
Operations And Organization [Line Items]
Number of operating facilities	1

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
	Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of stock options granted	10 years
Stock-based compensation plans	6
Percentage of market value of common stock, stock options exercise price	100.00%
Percentage of market value of common stock, restricted stock award granted	100.00%
Stock-based compensation award, vesting period	3 years
Total unrecognized stock-based compensation	$881
Stock-based compensation awards, weighted-average period recognized	1 year 5 months 5 days
Restricted stock granted during period	110,000
Weighted-average grant date fair value of restricted stock granted	$5.23
Restricted Stock Awards [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period	1 year
Restricted Stock Awards [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period	3 years
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized stock-based compensation	$4,079
Stock-based compensation awards, weighted-average period recognized	3 years 7 months 21 days
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period	1 year
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation award, vesting period	5 years
2015 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock allowed to be issued	4,656,587

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Options Outstanding, Exercisable and Available for Grant (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Outstanding, Number of Shares	5,735,784
Granted, Number of Shares	915,000
Exercised, Number of Shares	-235,500
Forfeited or expired, Number of Shares	-24,500
Outstanding, Number of Shares	6,390,784
Vested or expected to vest, Number of Shares	6,062,442
Exercisable, Number of Shares	3,720,984
Available for grant, Number of Shares	686,587
Outstanding, Weighted Average Exercise Price	$4.34
Granted, Weighted Average Exercise Price	$5.23
Exercised, Weighted Average Exercise Price	$3.03
Forfeited or expired, Weighted Average Exercise Price	$3.96
Outstanding, Weighted Average Exercise Price	$4.52
Vested or expected to vest, Weighted Average Exercise Price	$4.51
Exercisable, Weighted Average Exercise Price	$4.70
Outstanding, Weighted Average Remaining Contractual Life (Years)	6 years 1 month 13 days
Vested or expected to vest, Weighted Average Remaining Contractual Life (Years)	5 years 11 months 9 days
Exercisable, Weighted Average Remaining Contractual Life (Years)	4 years 4 months 10 days
Outstanding, Aggregate Intrinsic Value	$5,569
Vested or expected to vest, Aggregate Intrinsic Value	5,408
Exercisable, Aggregate Intrinsic Value	$3,477

StockBased_Compensation_Other_

Stock-Based Compensation - Other Information Concerning Stock Options (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value of stock options granted	$2.48	$1.84
Aggregate intrinsic value of stock options exercised	$510	$51

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation Recognized (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$573	$490
Costs of Processing and Distribution [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	33	33
Marketing, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	525	442
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$15	$15

Net_Income_Loss_Per_Common_Sha2

Net Income (Loss) Per Common Share - Reconciliation of Common Stock Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Basic shares	57,087,497	56,451,646
Effect of dilutive securities: Stock options	861,727
Diluted shares	57,949,224	56,451,646

Net_Income_Loss_Per_Common_Sha3

Net Income (Loss) Per Common Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS	50,000	50,000
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS		282,606
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive stock excluded from the computation of diluted EPS	1,695,436	4,214,548

Inventories_Components_of_Inve

Inventories - Components of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Unprocessed tissue and raw materials	$29,285	$29,429
Tissue and work in process	43,042	44,688
Implantable tissue and finished goods	40,380	37,150
Supplies	2,201	2,197
Inventory - net	$114,908	$113,464

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Inventory Disclosure [Abstract]
Provision for inventory write-downs	$1,196	$1,314

Property_Plant_and_Equipment_C

Property, Plant and Equipment - Components of Property, Plant and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$142,168	$139,909
Less accumulated depreciation	-64,878	-62,881
Property, plant and equipment, net	77,290	77,028
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,305	2,474
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	62,808	49,483
Processing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	46,288	45,878
Surgical Instruments [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	10,492	9,428
Office Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,137	3,863
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,428	7,674
Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	8,559	20,957
Office Equipment Under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$151	$152

PropertyPlant_and_Equipment_Ad

Property,Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense of property, plant and equipment	$2,944	$2,536

Other_Intangible_Assets_Compon

Other Intangible Assets - Components of Other Intangible Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$44,321	$44,612
Accumulated Amortization	15,192	14,351
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	11,328	11,420
Accumulated Amortization	2,875	2,727
Acquired Licensing Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,850	10,850
Accumulated Amortization	6,841	6,538
Marketing and Procurement Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	22,143	22,342
Accumulated Amortization	$5,476	$5,086

Other_Intangible_Assets_Additi

Other Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense of other intangible assets	$1,022	$1,128

Other_Intangible_Assets_Estima

Other Intangible Assets - Estimates of Future Amortization Expense (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$3,000
2016	3,400
2017	3,300
2018	3,300
2019	3,300
Total future amortization expense	$16,300

Other_Assets_Schedule_of_Other

Other Assets - Schedule of Other Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Indemnification assets	$11,342	$11,394	$13,000
Other	633	876
Total other assets	$11,975	$12,270

Other_Assets_Additional_Inform

Other Assets - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Jul. 16, 2013	Dec. 31, 2014	Dec. 31, 2013
Other Assets [Line Items]
Deposit in escrow account	$13,000
Indemnification assets	11,342			11,394	13,000
Indemnification liability	11,342			11,394	13,000
Claim period end date against escrow account	16-Oct-14
Extended claim period against escrow account	30 months
Interest expense associated with the amortization of debt issuance costs	35	35
Pioneer [Member]
Other Assets [Line Items]
Business acquisition, agreement date	12-Jun-13
Business acquisition, cash consideration			$126,307
Business acquisition date	16-Jul-13

Accrued_Expenses_Accrued_Expen

Accrued Expenses - Accrued Expenses (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Accrued compensation	$5,787	$6,220
Accrued severance charges	1,413	2,771
Accrued distributor commissions	2,256	3,159
Accrued donor recovery fees	2,860	3,249
Accrued taxes	1,737	1,249
Accrued restructuring charges		13
Other	6,875	8,028
Total accrued expenses	$20,928	$24,689

Short_and_LongTerm_Obligations2

Short and Long-Term Obligations - Short and Long-Term Obligations (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
Term loan	$57,875	$59,375
Credit facilities	16,798	16,435
Capital leases	69	82
Debt and capital lease obligation, total	74,742	75,892
Debt and capital lease obligation, total	74,742	75,892
Less current portion	-6,467	-6,479
Long-term portion	$68,275	$69,413

Short_and_LongTerm_Obligations3

Short and Long-Term Obligations - Additional Information (Detail)

3 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2015

Dec. 31, 2014

Mar. 31, 2015

Mar. 31, 2015

Jul. 16, 2013

Jul. 16, 2013

Jul. 16, 2013

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

Mar. 31, 2015

USD ($)

USD ($)

Credit Facilities [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

TD Bank and Regions Bank [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

German Banks [Member]

Debt_Instruments

USD ($)

USD ($)

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Senior Secured Facility [Member]

Revolving Credit Facility [Member]

Bank Term Loan [Member]

USD ($)

EUR (€)

Revolving Credit Facility [Member]

Secured by Mortgage [Member]

Secured by Accounts Receivable [Member]

Minimum [Member]

Maximum [Member]

USD ($)

USD ($)

Debt_Instruments

Debt_Instruments

USD ($)

EUR (€)

EUR (€)

Line of Credit Facility [Line Items]

Term of senior secured credit facility

5 years

Amount of senior secured facility obtained

$80,000,000

$20,000,000

$60,000,000

Maturity date of senior secured credit facility

16-Jul-18

Variable interest rate range

1.00%

1.75%

Credit outstanding

16,798,000

16,435,000

15,250,000

1,548,000

Description of variable interest rate basis

One month LIBOR rate

Revolving credit facility, variable interest rate

1.68%

Aggregate principal payment on term loan

18,000,000

Minimum cash balance required for covenant compliance

10,000,000

Covenant Terms of Credit Facility

The new credit agreement also contains various restrictive covenants which limit, among other things, indebtedness and liens, as well as payment of dividends, while requiring a minimum cash balance on hand of $10,000 and certain financial covenant ratios.

Long-term obligations outstanding, number

4

3

3

Credit facility, borrowing capacity

1,845,000

1,700,000

Revolving credit facility

1,000,000

500,000

Unsecured revolving credit facility

200,000

Minimum interest rate

1.49%

2.55%

2.55%

Maximum interest rate

2.85%

8.50%

8.50%

Current borrowing capacity

5,047,000

Maturity date of capital leases

2017

Future maturities of capital leases

69,000

82,000

Interest included in minimum lease payments

1,000

Present value of minimum lease payments

$68,000

Short_and_LongTerm_Obligations4

Short and Long-Term Obligations - Contractual Maturities of Short and Long-Term Obligations (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule Of Short Term And Long Term Debt [Line Items]
2015	$5,330
2016	4,533
2017	5,254
2018	59,625
Debt and capital lease obligation, total	74,742	75,892
Term Loan [Member]
Schedule Of Short Term And Long Term Debt [Line Items]
2015	3,750
2016	4,500
2017	5,250
2018	44,375
Debt and capital lease obligation, total	57,875
Credit Facilities [Member]
Schedule Of Short Term And Long Term Debt [Line Items]
2015	1,548
2018	15,250
Debt and capital lease obligation, total	16,798
Capital Leases [Member]
Schedule Of Short Term And Long Term Debt [Line Items]
2015	32
2016	33
2017	4
Debt and capital lease obligation, total	$69

Other_LongTerm_Liabilities_Sch

Other Long-Term Liabilities - Schedule of Other Long-Term Liabilities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Indemnification liability	$11,342	$11,394	$13,000
Other	196	213
Total other long-term liabilities	$11,538	$11,607

Other_LongTerm_Liabilities_Add

Other Long-Term Liabilities - Additional Information (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]
Indemnification liability	$11,342	$11,394	$13,000

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Deferred tax assets	$28,103
Deferred tax assets, valuation allowances	906
Primary measure of cumulative losses, number of rolling years	3 years
Utilized percentage of deferred tax assets before expiration	100.00%
Foreign Tax Authority [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Income tax examination year	2010
Foreign Tax Authority [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Income tax examination year	2012
Domestic [Member]
Operating Loss Carryforwards [Line Items]
Deferred tax assets, valuation allowances	$906	$959

Preferred_Stock_Additional_Inf

Preferred Stock - Additional Information (Detail) (Private Placement with WSHP [Member], USD $)	0 Months Ended
In Thousands, unless otherwise specified	Jun. 12, 2013
Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible preferred stock issued	$50,000
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred stock dividend rate	6.00%

Preferred_Stock_Schedule_of_Pr

Preferred Stock - Schedule of Preferred Stock (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Temporary Equity [Line Items]
Preferred shares issuance costs	($1,290)	($1,290)
Net proceeds	48,710	48,710
Amortization of preferred shares issuance costs	307	261
Accrued dividend payable	4,671	3,863
Total	53,688	52,834
Series A Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred shares issuance	50,000	50,000
Amortization of preferred shares issuance costs	$46

Restructuring_Charges_Addition

Restructuring Charges - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Restructuring and Related Activities [Abstract]
Expenses for integration activities	$2,881

Restructuring_Charges_Schedule

Restructuring Charges - Schedule of Restructuring Charges (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Accrued restructuring charges, beginning balance	$13
Cash payments	-13
Accrued restructuring charges, ending balance

Severance_Charges_Additional_I

Severance Charges - Additional Information (Detail) (USD $)	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Severance charges related to the termination of former employees	$4,798
Minimum [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Severance payment period		1 month
Maximum [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Severance payment period		12 months

Severance_Charges_Schedule_of_

Severance Charges - Schedule of Severance Charges (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Accrued restructuring charges, beginning balance	$13
Severance cash payments	-13
Accrued restructuring charges, ending balance
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Accrued restructuring charges, beginning balance	2,771
Severance cash payments	-1,048
Stock based compensation	-310
Accrued restructuring charges, ending balance	$1,413

Legal_Actions_Additional_Infor

Legal Actions - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Claims
Loss Contingencies [Line Items]
Outstanding claims	0
Tissue Only Claims [Member]
Loss Contingencies [Line Items]
Claims for which the Company Parties are providing defense and indemnification	333
Tissue Non Coloplast Claims[Member]
Loss Contingencies [Line Items]
Claims for which the Company Parties are providing defense and indemnification	354

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Jul. 13, 2009	Mar. 31, 2015	Mar. 31, 2013	Dec. 31, 2010
Commitment And Contingencies [Line Items]
Exclusivity payments		$3,500
Deferred revenue recognition		2,000
Davol, Inc. [Member]
Commitment And Contingencies [Line Items]
Non-refundable license fee	8,000
Revenue milestone payment				3,500
Exclusivity payments		8,000
Initial agreement term		10 years
Exclusive worldwide distribution agreement, extended expiration date		13-Jul-19
Deferred revenue recognition		$1,500	$1,715

Segment_Data_Additional_Inform

Segment Data - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of reportable segments	1
Lines of business	6

Segment_Data_Revenues_from_Tis

Segment Data - Revenues from Tissue Distribution and Other Revenues (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Other revenues	$4,217	$2,756
Total revenues	68,034	60,745
Domestic [Member]
Segment Reporting Information [Line Items]
Revenues	62,688	54,815
International [Member]
Segment Reporting Information [Line Items]
Revenues	5,346	5,930
Spine [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	19,379	19,063
Sports Medicine [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	12,107	11,360
BGS and General Orthopedic [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	10,929	8,147
Ortho Fixation [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	10,637	7,495
Surgical Specialties [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	6,010	7,278
Dental [Member] | Tissue Distribution [Member]
Segment Reporting Information [Line Items]
Tissue distribution	$4,755	$4,646

Segment_Data_Schedule_of_Perce

Segment Data - Schedule of Percentage of Total Revenues Derived from Company's Largest Distributors and International Distribution (Detail) (Distributors Concentration Risk [Member], Sales Revenue, Net [Member])	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Zimmer, Inc. [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	20.00%	17.00%
Medtronic, Inc. [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	9.00%	14.00%
Davol, Inc. [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	4.00%	7.00%
International Customers [Member]
Concentration Risk [Line Items]
Percentage of sales revenue	8.00%	10.00%

Segment_Data_Schedule_of_Prope

Segment Data - Schedule of Property, Plant and Equipment - Net by Significant Geographic Location (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	$77,290	$77,028
Domestic [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	64,590	63,009
International [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment - net	$12,700	$14,019